Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Beta Bionics, Inc. (NASDAQ: BBNX)
Beta Bionics, Inc. (BBNX)
Company Research
Source: GlobeNewswire
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Beta Bionics is a medical device company engaged in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. On January 8, 2026, after markets closed, Beta Bionics announced its preliminary, unaudited topline financial results and key metrics for the fourth quarter of 2025. The Company reported “[n]ew patient starts expected to be at least 5,581” for the fourth quarter of 2025. An analyst at Bloomberg reportedly stated that “Beta’s 5,581 new-pat
Show less
Read more
Impact Snapshot
Event Time:
BBNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBNX alerts
High impacting Beta Bionics, Inc. news events
Weekly update
A roundup of the hottest topics
BBNX
News
- Beta Bionics (NASDAQ:BBNX) had its price target lowered by analysts at Truist Financial Corporation from $37.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNXPR Newswire
- SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta BionicsPR Newswire
- BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law FirmGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Beta Bionics, Inc. - BBNXGlobeNewswire
BBNX
Earnings
- 10/28/25 - Beat
BBNX
Sec Filings
- 1/30/26 - Form 8-K
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- BBNX's page on the SEC website